Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Aurum Pharmaceuticals Ltd, Bampton Road, Harold Hill, Romford, Essex, RM3 8UG, United Kingdom
Prenoxad 1mg/ml Solution for Injection in a pre-filled syringe.
| Pharmaceutical Form |
|---|
|
Solution for injection/infusion in a pre-filled syringe. Sterile, clear and colourless liquid with a pH of 3.0-4.0 and osmolarity 270 to 300 mOsmol/L. |
The active substance is Naloxone Hydrochloride 1 mg/ml.
1 ml of solution – contains 1 mg of naloxone hydrochloride.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Naloxone |
Naloxone hydrochloride, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors. It reveals very high affinity for the opioid receptor sites and therefore displaces both opioid agonists and partial antagonists, such as pentazocine, for example, but also nalorphine. |
| List of Excipients |
|---|
|
Sodium chloride |
Sterile solution for injection presented in a Glass (Type I) 2ml prefilled syringe. The pack contains two 23G x 1¼" needles.
Aurum Pharmaceuticals Ltd, Bampton Road, Harold Hill, Romford, Essex, RM3 8UG, United Kingdom
PL 12064/0125
Date of first authorisation : 29/06/2012
| Drug | Countries | |
|---|---|---|
| PRENOXAD | Australia, Estonia, France, Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
